2Brenner BM, CooperME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001, 345:861.
3Lewis EJ, Hunsicker LG, ClarkeWR, et al. Renop rotective effect of the angiotensin2recep tor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl JMed, 2001, 345:851.
4Parring HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 2001, 345:870.
5Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (L IFE):A randomised trial against atenolol. Lancet, 2002, 359:1004.
6Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin- Ⅱ receptor blocker and angiotensin convert ingenzyme inhibitor in non-diabetic renal disease (COOPERATE):A randomised controlled trial. Lancet, 2003, 361:117.
3SAEGUSA S, FEI Y, TAKAHASHI T, et al. Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponeetin expression[J]. Cardiovasc Drugs Ther, 2007, 21(3): 155-160.
4WAKI M, MATSUDA M, MAEDA N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors[J]. Diabetes, 2003, 52(7): 1655- 1663.
5WAKI M, MATSUDA M, MAEDA N, etal. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors[J]. Diabetes, 2003, 52(7): 1655-1663.
6HATTORI Y, AKIMOTO K, GROSS SS, et al. Angiotensin-Ⅱ- induced oxidative stress elicits hypoadiponectinaemia in rats [J]. Diabetologia, 2005, 48(6): 1066-1074.
7ZHU XY, DAGHINI E, RODRIGUEZ-PORCEL M, et al. Redoxsensilive myocardial remodeling and dysfunction in swine diet-induced experimental hypercholesterolemia[J]. Athernsclerosis, 2007, 193(1 ): 62-69.
8CSONT T, BERECZKI E, BENCSIK P, et al. Hypercholes-terolcmia increases myocardial oxidative and nitrosative stress thereby leading to cardiac dysfunction in apoB-100 transgenic mice[J]. Cardiovasc Res, 2007, 76(1): 100-109.
9GILARDINI L, MCTERNAN PG, GIROLA A, et al. Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents[J]. Atherosclerosis, 2006, 189 (2): 401-407.
10OKUI H, HAMASAKI S, ISHIDA S, et al. Adiponectin is a better predictor of endothelial function of the coronary artery than HOMA-R, body mass index, immunoreactive insulin, or triglycerides[J]. Int J Cardio, 2008, 126(1): 53-61.
2HOLLENBERG.Aldosterone in the development and progression of renal injury[J].Kidney Int,2004,66(1):1-9.
3BRIET M,SCHIFFRIN EL.Aldosterone:effects on the kidney and cardiovascular system[J].Nat Rev Nephrol,2010,6(5):261-273.
4NAGASE M,FUJITA T.Aldosterone and glomerular podocyte injury[J].Clin Exp Nephrol.2008,12(4):233-242.
5NAGASE M.Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome[J].Clin Exp Nephrol,2010,14(4):303-314.
